The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes
© 2024. Asian Pacific Association for the Study of the Liver..
BACKGROUND AND AIMS: Data on the effects of liver fibrosis and hepatic steatosis on outcomes in individuals living with diabetes are limited. Therefore, we investigated the predictive value of the fibrosis and the severity of hepatic steatosis for all-cause mortality in individuals living with diabetes.
METHODS: A total of 1903 patients with diabetes from the Third National Health and Nutrition Examination Survey (NHANES III) dataset were enrolled. Presumed hepatic fibrosis was evaluated with Fibrosis-4 index (FIB-4). The mortality risk and corresponding hazard ratio (HR) were analyzed with the Kaplan-Meier method and multivariable Cox proportional hazard models.
RESULTS: Over a median follow-up of 19.4 years, all-cause deaths occurred in 69.6%. FIB-4 ≥ 1.3 was an independent predictor of mortality in individuals living with diabetes (HR 1.219, 95% confidence interval [CI]: 1.067-1.392, p = 0.004). Overall, FIB-4 ≥ 1.3 without moderate-severe steatosis increased the mortality risk (HR 1.365; 95%CI 1.147-1.623, p < 0.001). The similar results were found in individuals living with diabetes with metabolic dysfunction-associated fatty liver disease (MAFLD) (HR 1.499; 95%CI 1.065-2.110, p = 0.020), metabolic syndrome (MetS) (HR 1.397; 95%CI 1.086-1.796, p = 0.009) or abdominal obesity (HR 1.370; 95%CI 1.077-1.742, p = 0.010).
CONCLUSIONS: Liver fibrosis, as estimated by FIB-4, may serve as a more reliable prognostic indicator for individuals living with diabetes than hepatic steatosis. Individuals living with diabetes with FIB-4 ≥ 1.3 without moderate-severe steatosis had a significantly increased all-cause mortality risk. These findings highlight the importance of identifying and monitoring those individuals, as they may benefit from further evaluation and risk stratification.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Hepatology international - (2024) vom: 22. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Xiaoyan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abdominal obesity |
|---|
| Anmerkungen: |
Date Revised 22.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s12072-023-10625-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367428652 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367428652 | ||
| 003 | DE-627 | ||
| 005 | 20240122232241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12072-023-10625-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1267.xml |
| 035 | |a (DE-627)NLM367428652 | ||
| 035 | |a (NLM)38252365 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Xiaoyan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. Asian Pacific Association for the Study of the Liver. | ||
| 520 | |a BACKGROUND AND AIMS: Data on the effects of liver fibrosis and hepatic steatosis on outcomes in individuals living with diabetes are limited. Therefore, we investigated the predictive value of the fibrosis and the severity of hepatic steatosis for all-cause mortality in individuals living with diabetes | ||
| 520 | |a METHODS: A total of 1903 patients with diabetes from the Third National Health and Nutrition Examination Survey (NHANES III) dataset were enrolled. Presumed hepatic fibrosis was evaluated with Fibrosis-4 index (FIB-4). The mortality risk and corresponding hazard ratio (HR) were analyzed with the Kaplan-Meier method and multivariable Cox proportional hazard models | ||
| 520 | |a RESULTS: Over a median follow-up of 19.4 years, all-cause deaths occurred in 69.6%. FIB-4 ≥ 1.3 was an independent predictor of mortality in individuals living with diabetes (HR 1.219, 95% confidence interval [CI]: 1.067-1.392, p = 0.004). Overall, FIB-4 ≥ 1.3 without moderate-severe steatosis increased the mortality risk (HR 1.365; 95%CI 1.147-1.623, p < 0.001). The similar results were found in individuals living with diabetes with metabolic dysfunction-associated fatty liver disease (MAFLD) (HR 1.499; 95%CI 1.065-2.110, p = 0.020), metabolic syndrome (MetS) (HR 1.397; 95%CI 1.086-1.796, p = 0.009) or abdominal obesity (HR 1.370; 95%CI 1.077-1.742, p = 0.010) | ||
| 520 | |a CONCLUSIONS: Liver fibrosis, as estimated by FIB-4, may serve as a more reliable prognostic indicator for individuals living with diabetes than hepatic steatosis. Individuals living with diabetes with FIB-4 ≥ 1.3 without moderate-severe steatosis had a significantly increased all-cause mortality risk. These findings highlight the importance of identifying and monitoring those individuals, as they may benefit from further evaluation and risk stratification | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Abdominal obesity | |
| 650 | 4 | |a All-cause mortality | |
| 650 | 4 | |a Fibrosis | |
| 650 | 4 | |a MAFLD | |
| 650 | 4 | |a Mets | |
| 650 | 4 | |a NHANES III | |
| 650 | 4 | |a Predictor | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Risk factor | |
| 650 | 4 | |a Risk stratification | |
| 700 | 1 | |a Zhu, Yixuan |e verfasserin |4 aut | |
| 700 | 1 | |a Yeo, Yee Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Zhiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xiaoming |e verfasserin |4 aut | |
| 700 | 1 | |a Rui, Fajuan |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Wenjing |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Shengxia |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Xiaolong |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Junping |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology international |d 2007 |g (2024) vom: 22. Jan. |w (DE-627)NLM190585528 |x 1936-0541 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:22 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12072-023-10625-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 22 |c 01 | ||